Recommendation of the President – Calcort (deflazacort)
On 11 December 2024, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 142/2024 on the appraisal on the appropriateness of issuing approvals for the reimbursement of the medicinal product Calcort (deflazacort) for the indication Duchenne muscular dystrophy